p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775

The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21 (HCT116 p21(-/-), RPE p21(-/-), and U2OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauge, Sissel, Macurek, Libor, Syljuåsen, Randi G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527284/
https://www.ncbi.nlm.nih.gov/pubmed/30943845
http://dx.doi.org/10.1080/15384101.2019.1593649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527284/
https://www.ncbi.nlm.nih.gov/pubmed/30943845
http://dx.doi.org/10.1080/15384101.2019.1593649

Ejemplares similares